No serious adverse events in Covaxin Phase 1 trials

Bharat Biotech's indigenously developed Covid-19 vaccine, Covaxin, was well tolerated and did not report any serious adverse events during the study conducted in phase 1 trials, as per results published in The Lancet, the prestigious British medical journal.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/39Vn6Sz
via IFTTT